FOR HEALTHCARE PROFESSIONALS

IMPORTAND INFORMATION ABOUT IMDELLTRA (tarlatamab)

IMPORTANT INFORMATION YOU SHOULD KNOW:

- This patient is being treated with IMDELLTRA®, which is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumour cells and CD3 expressed on the surface of T cells
- IMDELLTRA® is used for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- IMDELLTRA® may cause side effects which may be severe and life-threatening such as Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

IMDELLTRA®
(tarlatamab)

FOR HEALTHCARE PROFESSIONALS

For further information on IMDELLTRA® and the management of CRS and ICANS with IMDELLTRA® (tarlatamab), please refer to the Prescribing Information (PI) available at:
https://israeldrugs.health.gov.il/#!/medDetails/178%2021%2037927%2000

If this patient is experiencing any of the symptoms on this card, please contact the prescribing doctor immediately for further information.

ACTIONS FOR PATIENTS/CAREGIVERS

You are required to stay within 1 hour of an appropriate healthcare setting such as the treatment hospital for 48 hours starting from each IMDELLTRA® infusion on Day 1 and Day 8, accompanied by a caregiver.

CONTACT your prescribing doctor if you experience any of the symptoms listed in this card.

GO to the hospital emergency room if you cannot reach your prescribing doctor's office.

REFRAIN from driving, operating heavy or potentially dangerous machinery, and engaging in hazardous occupations or activities following IMDELLTRA® infusion if there are ICANS-associated neurological symptoms, such as dizziness, seizures, and confusion, until these symptoms resolve.

IMDELLTRA® (tarlatamab) PATIENT ALERT CARD

To be completed by the prescribing doctor

THIS PATIENT HAS RECEIVED IMDELLTRA®

Patient name/phone number: _____

Date & time of first IMDELLTRA® infusion:

_____

Prescribing Doctor name/phone number:

_____

Emergency contact name/phone number:

_____

Name of Hospital/Centre/Institution:

_____

IMPORTANT INFORMATION FOR PATIENTS RECEIVING TREATMENT WITH IMDELLTRA®

FOR PATIENTS/CAREGIVERS

IMDELLTRA® can cause serious and/or life-threatening side effects, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Call your prescribing doctor or seek emergency medical attention right away if you experience any of these symptoms.

Cytokine Release Syndrome (CRS)

- fever of 38°C or higher
- low blood pressure
- tiredness
- fast heartbeat or dizziness
- chills
- headache
- shortness of breath or trouble breathing
- hypoxia
- nausea and vomiting
- confusion
- restlessness, or feeling anxious
- problems with balance and movement, such as trouble walking

Immune effector cell-associated neurotoxicity syndrome (ICANS)

- trouble speaking
- memory loss, or personality changes
- confusion, delirium, feeling disoriented, slow thinking or not being able to think clearly
- seizure
- problems with walking or loss of balance or coordination
- weakness or numbness of your arms or legs
- shakiness (tremor)
- headache
- numbness or tingling of your hands or feet
- dizziness
- fainting or loss of consciousness
- muscular weakness
- somnolence

If you have any of these symptoms, call your prescribing doctor or seek emergency medical attention right away. These are not all of the possible side effects of **IMDELLTRA®**. Please refer to the Patient Leaflet for a full list of possible side effects.

Tell your prescribing doctor if you have any symptom that bothers you or does not go away.

FOR PATIENTS/CAREGIVERS

You should always consult your prescribing doctor about taking other medications while taking IMDELLTRA®.

IMPORTANT TO REMEMBER:

You are required to stay within 1 hour of an appropriate healthcare setting, such as the treatment hospital for 48 hours starting from each IMDELLTRA® infusion on Day 1 and Day 8, accompanied by a caregiver. If you are unsure of what an appropriate healthcare setting is, please ask your doctor.

This is required in case you develop serious side effects and need to seek immediate medical attention.

MORE INFORMATION:

If you require further information on IMDELLTRA® please refer to the patient leaflet or online at:
https://israeldrugs.health.gov.il/#!/byDrug

or
contact our local distributor Medison Pharma Medical Information by email at
medinfoisrael@medisonpharma.com.

Adverse events can be reported to the Ministry of Health via

https://sideeffects.health.gov.il

Or
report to local distributor Medison:

PVIsrael@Medisonpharma.com

IMDELLTRA® (tarlatamab) PATIENT ALERT CARD FOR PATIENTS/CAREGIVERS

- You must carry this card with you at all times
- Contact your prescribing doctor or go to the hospital emergency room or call 101 if you experience any symptoms listed in this card
- **SHOW THIS CARD** to any healthcare professional involved in your care and if you go to the hospital emergency room

This card and its contents were approved by the Ministry of Health in December 2025
Version 1.0